{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:54:03Z","timestamp":1781362443725,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Biotron Limited","award":["ASX:BIT"],"award-info":[{"award-number":["ASX:BIT"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>BIT225 is a first-in-class inhibitor of human immunodeficiency virus (HIV) type 1 Vpu. A phase II trial enrolled 36 HIV-1\u2013infected, treatment-naive participants in Thailand to receive standard-of-care antiretroviral therapy (ART), tenofovir disoproxil fumarate\/emtricitabine\/efavirenz (Atripla), with 100 or 200 mg of BIT225 or placebo (daily) for 12 weeks. Combined treatment with BIT225 and ART was found to be generally safe and well tolerated, with antiviral efficacy comparable to that of ART alone. The secondary end point\u2014soluble CD163, a marker of monocyte\/macrophage inflammation\u2014was noted to be significantly decreased in the BIT225 arm. Plasma-derived activated CD4+ and CD8+ T cells, natural killer cells, and interleukin 21 were increased in those treated with BIT225. These findings are consistent with inhibition of the known effects of HIV Vpu and may reflect clinically important modulation of inflammatory and immune function. Further clinical study is planned to both confirm and extend these important findings in treatment-naive, and treatment-experienced individuals.<\/jats:p>\n               <jats:p>Clinical Trials Registration. Australian New Zealand Clinical Trials Registry (Universal Trial Number U1111-1191-2194).<\/jats:p>","DOI":"10.1093\/infdis\/jiaa635","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:17:10Z","timestamp":1601983030000},"page":"1914-1922","source":"Crossref","is-referenced-by-count":18,"title":["Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation"],"prefix":"10.1093","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1153-2099","authenticated-orcid":false,"given":"Carolyn A","family":"Luscombe","sequence":"first","affiliation":[{"name":"Biotron Limited, North Ryde, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand"},{"name":"Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuanchai","family":"Supparatpinyo","sequence":"additional","affiliation":[{"name":"Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaporn","family":"Gatechompol","sequence":"additional","affiliation":[{"name":"HIV-Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand"},{"name":"Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Win Min","family":"Han","sequence":"additional","affiliation":[{"name":"HIV-Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D","family":"Ewart","sequence":"additional","affiliation":[{"name":"Biotron Limited, North Ryde, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey S","family":"Thomson","sequence":"additional","affiliation":[{"name":"Biotron Limited, North Ryde, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Miller","sequence":"additional","affiliation":[{"name":"Biotron Limited, North Ryde, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Becker","sequence":"additional","affiliation":[{"name":"Biotron Limited, North Ryde, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Murphy","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"2021060422093507100_CIT0001","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/334532a0","article-title":"Identification of a protein encoded by the vpu gene of HIV-1","volume":"334","author":"Cohen","year":"1988","journal-title":"Nature"},{"key":"2021060422093507100_CIT0002","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.3261888","article-title":"A novel gene of HIV-1, vpu, and its 16-kilodalton product","volume":"241","author":"Strebel","year":"1988","journal-title":"Science"},{"key":"2021060422093507100_CIT0003","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1097-2765(00)80056-8","article-title":"A novel human WD protein, h-\u03b2TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif","volume":"1","author":"Margottin","year":"1998","journal-title":"Mol Cell"},{"key":"2021060422093507100_CIT0004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/157016212800792513","article-title":"HIV-1 Vpu interference with innate cell-mediated immune mechanisms","volume":"10","author":"Sandberg","year":"2012","journal-title":"Curr HIV Res"},{"key":"2021060422093507100_CIT0005","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.3390\/v7082824","article-title":"Vpu protein: the viroporin encoded by HIV-1","volume":"7","author":"Gonz\u00e1lez","year":"2015","journal-title":"Viruses"},{"key":"2021060422093507100_CIT0006","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/1535370217697384","article-title":"Various plus unique: viral protein U as a plurifunctional protein for HIV-1 replication","volume":"242","author":"Soper","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"2021060422093507100_CIT0007","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1172\/JCI84456","article-title":"Macrophages sustain HIV replication in vivo independently of T cells","volume":"126","author":"Honeycutt","year":"2016","journal-title":"J Clin Invest"},{"key":"2021060422093507100_CIT0008","doi-asserted-by":"crossref","first-page":"e03395-19","DOI":"10.1128\/mBio.03395-19","article-title":"The HIV-1 accessory protein Vpu downregulates peroxisome biogenesis","volume":"11","author":"Xu","year":"2020","journal-title":"mBio"},{"key":"2021060422093507100_CIT0009","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/AAC.01308-09","article-title":"Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages","volume":"54","author":"Khoury","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021060422093507100_CIT0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12981-016-0093-z","article-title":"The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells","volume":"13","author":"Khoury","year":"2016","journal-title":"AIDS Res Ther"},{"key":"2021060422093507100_CIT0011","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/jac\/dkv389","article-title":"A phase 1b\/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection","volume":"71","author":"Wilkinson","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021060422093507100_CIT0012","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro2820","article-title":"Viroporins: structure and biological functions","volume":"10","author":"Nieva","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"2021060422093507100_CIT0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-5793(03)00782-8","article-title":"Vpu from HIV-1 on an atomic scale: experiments and computer simulations","volume":"552","author":"Fischer","year":"2003","journal-title":"FEBS Lett"},{"key":"2021060422093507100_CIT0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tim.2013.05.001","article-title":"The HIV-1 containing macrophage compartment: a perfect cellular niche?","volume":"21","author":"Tan","year":"2013","journal-title":"Trends Microbiol"},{"key":"2021060422093507100_CIT0015","doi-asserted-by":"crossref","first-page":"e00020-19","DOI":"10.1128\/JVI.00020-19","article-title":"Contribution of the cytoplasmic determinants of Vpu to the expansion of virus-containing compartments in HIV-1-infected macrophages","volume":"93","author":"Leymarie","year":"2019","journal-title":"J Virol"},{"key":"2021060422093507100_CIT0016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chom.2009.01.009","article-title":"HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor","volume":"5","author":"Goffinet","year":"2009","journal-title":"Cell Host Microbe"},{"key":"2021060422093507100_CIT0017","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/157016210791111124","article-title":"The Vpu protein: new concepts in virus release and CD4 down-modulation","volume":"8","author":"Ruiz","year":"2010","journal-title":"Curr HIV Res"},{"key":"2021060422093507100_CIT0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"2021060422093507100_CIT0019","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","article-title":"The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein","volume":"3","author":"Van Damme","year":"2008","journal-title":"Cell Host Microbe"},{"key":"2021060422093507100_CIT0020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cells8091020","article-title":"Plasma membrane-associated restriction factors and their counteraction by HIV-1 accessory proteins","volume":"8","author":"Ramirez","year":"2019","journal-title":"Cells"},{"key":"2021060422093507100_CIT0021","article-title":"Vpu inhibitor BIT225 alters T cell activation and homing plasma membrane expression on CD4+ T cells(CD28 and CCR7) and monocyte-derived macrophages (CD80 and CD86)","author":"Luscombe"},{"key":"2021060422093507100_CIT0022","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1073\/pnas.85.18.6968","article-title":"Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome","volume":"85","author":"Matsuda","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021060422093507100_CIT0023","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jir520","article-title":"Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients","volume":"204","author":"Burdo","year":"2011","journal-title":"J Infect Dis"},{"key":"2021060422093507100_CIT0024","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/infdis\/jir214","article-title":"Soluble CD163 made by monocyte\/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy","volume":"204","author":"Burdo","year":"2011","journal-title":"J Infect Dis"},{"key":"2021060422093507100_CIT0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/QAD.0b013e32836010bd","article-title":"Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection","volume":"27","author":"Burdo","year":"2013","journal-title":"AIDS"},{"key":"2021060422093507100_CIT0026","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/infdis\/jiw263","article-title":"Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals","volume":"214","author":"Knudsen","year":"2016","journal-title":"J Infect Dis"},{"key":"2021060422093507100_CIT0027","doi-asserted-by":"crossref","first-page":"e55279","DOI":"10.1371\/journal.pone.0055279","article-title":"Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women","volume":"8","author":"Martin","year":"2013","journal-title":"PLoS One"},{"key":"2021060422093507100_CIT0028","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/QAI.0000000000000329","article-title":"Soluble CD163 is associated with shortened telomere length in HIV-infected patients","volume":"67","author":"Srinivasa","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021060422093507100_CIT0029","volume-title":"R: a language and environment for statistical computing","author":"R Core Team.","year":"2019"},{"key":"2021060422093507100_CIT0030","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/v3071091","article-title":"The natural killer cell cytotoxic function is modulated by HIV-1 accessory proteins","volume":"3","author":"Sowrirajan","year":"2011","journal-title":"Viruses"},{"key":"2021060422093507100_CIT0031","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41564-018-0335-z","article-title":"HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy","volume":"4","author":"Ganor","year":"2019","journal-title":"Nat Microbiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa635\/34743436\/jiaa635.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/11\/1914\/38488282\/jiaa635.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/11\/1914\/38488282\/jiaa635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:45:43Z","timestamp":1622850343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/11\/1914\/5920638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2021,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa635","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,10,10]]}}}